Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEn4TmxKSzVyPUCuNFgzOzFiIN88US=>MlXKV2FPT0WU
SW756MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMUSwNlQhKM7:TR?=M{e4cXNCVkeHUh?=
CTV-1NH;wN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlqwTWM2OD1yLkG2N|k5KCEQvF2=Mom5V2FPT0WU
HSC-4NYXlZ2p[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:wcGk{UUN3ME2wMlE4OTV6IDFOwG0>MXPTRW5ITVJ?
LAMA-84MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e2UWlEPTB;MD6yPFY3PCBizszNNVK2UWtqW0GQR1XS
KU812NH\5V2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4C5RmlEPTB;MD6zOFA3QCBizszNMlHiV2FPT0WU
HCC1806NF7FUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\xTWM2OD1yLkO1NlE3KCEQvF2=M1PLdXNCVkeHUh?=
DOKMo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTBwM{e3PFYhKM7:TR?=MYfTRW5ITVJ?
NCI-H209NGLCSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jOfmlEPTB;MD60NFgxQCBizszNNX;6eWtPW0GQR1XS
EoL-1-cellMmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoKyTWM2OD1yLkSxOVc3KCEQvF2=MkHPV2FPT0WU
H9MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTBwNEO0OlQhKM7:TR?=MmjFV2FPT0WU
EM-2NWHUXmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3njbGlEPTB;MD60N|g6KCEQvF2=MmjuV2FPT0WU
NCI-H292NEW4fZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3m4TWlEPTB;MD60OFExQCBizszNMWTTRW5ITVJ?
697M2XBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDSV2JrUUN3ME2wMlQ2PjN|IDFOwG0>M{TTW3NCVkeHUh?=
BHT-101MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nPNWlEPTB;MD60OlU6KCEQvF2=M1K0dXNCVkeHUh?=
BE-13NVzRRoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF71O2ZKSzVyPUCuOFg2PzJiIN88US=>NIfjT49USU6JRWK=
RS4-11NWfae4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkG4TWM2OD1yLkS4OVg1KCEQvF2=MYPTRW5ITVJ?
IGROV-1MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrJPHBsUUN3ME2wMlQ5Pzl5IDFOwG0>NGS1W2JUSU6JRWK=
KE-37MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TGV2lEPTB;MD60PVUxQSBizszNNH3ze|ZUSU6JRWK=
BV-173NInrN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITafphKSzVyPUCuOVA4QTJiIN88US=>NWOwd4Q3W0GQR1XS
MEG-01NHOwT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnSbFZKSzVyPUCuOVEzOTRiIN88US=>M1X3OXNCVkeHUh?=
LB2241-RCCMkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwNUO3NVghKM7:TR?=MVjTRW5ITVJ?
ACHNNF3vZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwNUSwOlkhKM7:TR?=MVPTRW5ITVJ?
CTB-1NU\oeW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmn4TWM2OD1yLkW0PFIhKM7:TR?=NGP1NGxUSU6JRWK=
HT-1080NGLCempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\HRnRZUUN3ME2wMlU2OzR7IDFOwG0>MUTTRW5ITVJ?
CHL-1NHLPS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTBwNUW0OlUhKM7:TR?=MYrTRW5ITVJ?
EW-3MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwNUW5N|UhKM7:TR?=M4nre3NCVkeHUh?=
ES1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIi1e5ZKSzVyPUCuOlc1QThiIN88US=>MmjiV2FPT0WU
KASUMI-1NHi4SXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTBwN{KzN{Ah|ryPMWjTRW5ITVJ?
SW13NET2XmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXjTWM2OD1yLkezO|k5KCEQvF2=MU\TRW5ITVJ?
A3-KAWNX3WZ5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvJTWM2OD1yLke5NlA5KCEQvF2=M4n1cXNCVkeHUh?=
LB771-HNCMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHpUlhKSzVyPUCuPFMyODRiIN88US=>MYnTRW5ITVJ?
OC-314NVvDbIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfBPWdKSzVyPUCuPFY6PjViIN88US=>NHLafmhUSU6JRWK=
MLMANFziPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYriSYhxUUN3ME2wMlkxPjd3IDFOwG0>NImxbGRUSU6JRWK=
KARPAS-45M2XxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XGO2lEPTB;MD65NlQ3PiBizszNNH;IO25USU6JRWK=
CAL-27M{\KU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPETWM2OD1yLkmyPVA3KCEQvF2=MmPQV2FPT0WU
SK-NEP-1M{Tmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr0V3BDUUN3ME2wMlk4OjR6IDFOwG0>MV\TRW5ITVJ?
COR-L105NWLZfYFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTFwMECzPVQhKM7:TR?=NWLRVIozW0GQR1XS
TI-73NEDVXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXmTWM2OD1zLkCxOlUhKM7:TR?=MVfTRW5ITVJ?
JVM-3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXK4fVVWUUN3ME2xMlA2ODF5IDFOwG0>MlP5V2FPT0WU
HAL-01MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzaWW1vUUN3ME2xMlA5QDFiIN88US=>M4e3PHNCVkeHUh?=
QIMR-WILM2rjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTFwMEmwOVghKM7:TR?=MXHTRW5ITVJ?
HSC-3MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlWwTWM2OD1zLkGxO|g{KCEQvF2=MnvXV2FPT0WU
KY821M{jpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHzc5dKSzVyPUGuNVM{PTFiIN88US=>NEjoSpFUSU6JRWK=
5637M3TlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zNUGlEPTB;MT6xN|gxOyBizszNM3TQVXNCVkeHUh?=
CAL-33MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvjTWM2OD1zLkG5N|AzKCEQvF2=NFT5d|FUSU6JRWK=
ES4Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXxWJlkUUN3ME2xMlIxPzliIN88US=>Mk\xV2FPT0WU
BHYM4nzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjMe3BKSzVyPUGuNlI5QTJiIN88US=>MU\TRW5ITVJ?
LB1047-RCCM2\HeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rBRmlEPTB;MT6yN|c5PSBizszNM4HPSHNCVkeHUh?=
H4MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HyfWlEPTB;MT6yOFI2PSBizszNMnvGV2FPT0WU
RPMI-8866MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHyTWM2OD1zLkK2NVA3KCEQvF2=MVXTRW5ITVJ?
HO-1-N-1NGP0Z|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXHBS3IxUUN3ME2xMlI3OzZ7IDFOwG0>MV3TRW5ITVJ?
BB30-HNCNEO0NndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTFwMki3NVQhKM7:TR?=MnHSV2FPT0WU
PC-14NYn6WXRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTFwMkmyNFUhKM7:TR?=MmPnV2FPT0WU
NUGC-3MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYSw[2FSUUN3ME2xMlI6OzV4IDFOwG0>MoDhV2FPT0WU
A4-FukNYLN[XROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTFwM{C3NFQhKM7:TR?=MonsV2FPT0WU
MHH-NB-11MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jGXGlEPTB;MT6zNVM5OyBizszNM2nRN3NCVkeHUh?=
KOSC-2NVnSPZhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\ENlJKSzVyPUGuN|E4PzViIN88US=>MVLTRW5ITVJ?
A498MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2L6PWlEPTB;MT60NFEyOyBizszNNYj0e3VnW0GQR1XS
KG-1M2\a[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XQV2lEPTB;MT60NVI4OyBizszNNX3MSm1JW0GQR1XS
DELMoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4e5XWlEPTB;MT60N|Y2PyBizszNMVXTRW5ITVJ?
EW-16NYDUPGlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjHTWM2OD1zLkSzPVc{KCEQvF2=NW\BS3p{W0GQR1XS
BPH-1MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\qcmlEPTB;MT60OFgxPSBizszNNFX6fHZUSU6JRWK=
JARMm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLVO|NwUUN3ME2xMlQ6OzZiIN88US=>NWPVS3FqW0GQR1XS
J-RT3-T3-5Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzyc2VKSzVyPUGuOVE4OjJiIN88US=>NI\relRUSU6JRWK=
A375NEfOdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFy5fmVKSzVyPUGuOVE4PzJiIN88US=>NWfrR|NiW0GQR1XS
SW954Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTFwNUWwNFchKM7:TR?=MnL6V2FPT0WU
Ca9-22M2LYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHLclhDUUN3ME2xMlU3OjZiIN88US=>M336W3NCVkeHUh?=
D-566MGM3Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf3XIFvUUN3ME2xMlU4OTV3IDFOwG0>NHixdlFUSU6JRWK=
SCC-15NYftblgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;OPIJTUUN3ME2xMlYyQDB2IDFOwG0>MWnTRW5ITVJ?
HD-MY-ZNFuybVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrpTWM2OD1zLk[zOVg1KCEQvF2=MofSV2FPT0WU
HT-1376M4jzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4qwSmlEPTB;MT62OFM3KCEQvF2=MnHCV2FPT0WU
CAL-54NIHm[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\yOWlEPTB;MT62OVcxQSBizszNNE\Db29USU6JRWK=
ONS-76MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TM[WlEPTB;MT62O|U2OSBizszNMVfTRW5ITVJ?
EFO-27MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fyVmlEPTB;MT62PFkzKCEQvF2=NFXJemFUSU6JRWK=
769-PMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK0XXNKSzVyPUGuOlk2QTZiIN88US=>M4jPb3NCVkeHUh?=
MV-4-11M4XaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfHR2tKSzVyPUGuOlk5PTZiIN88US=>NY\vTW9SW0GQR1XS
NKM-1NGeyeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTFwN{G4NFIhKM7:TR?=NELFdHFUSU6JRWK=
LOXIMVIMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlL0TWM2OD1zLke0OVk6KCEQvF2=MX;TRW5ITVJ?
KYSE-140MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2[zSGlEPTB;MT63OVY2PSBizszNNWrxNIR7W0GQR1XS
ES5MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTFwOE[3OFchKM7:TR?=NGrvZlhUSU6JRWK=
BB65-RCCM3XBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHaTWM2OD1zLki5PFQ6KCEQvF2=MY\TRW5ITVJ?
HNMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmG4TWM2OD1zLki5PFc1KCEQvF2=M17vb3NCVkeHUh?=
A101DNIDETplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTFwOUO2NlghKM7:TR?=MknMV2FPT0WU
LoVoNHPrWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4HGe2lEPTB;MT65O|Y4QSBizszNM3PVOXNCVkeHUh?=
NCI-H526NVrzN2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLsdZVKSzVyPUGuPVk{OjViIN88US=>NXX2bFVjW0GQR1XS
NCI-H1693M1\G[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTmTWM2OD1zLkm5PFg5KCEQvF2=M3;X[XNCVkeHUh?=
OVCAR-4NHT3e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJwMEC0N|UhKM7:TR?=M33RZXNCVkeHUh?=
SK-HEP-1NYj1eWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjlcGxOUUN3ME2yMlAxPzR3IDFOwG0>MVLTRW5ITVJ?
C2BBe1NFvnUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJwMEOzO|IhKM7:TR?=MX;TRW5ITVJ?
MEL-JUSONVfOc4ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJwMES0OlQhKM7:TR?=NGq4dIZUSU6JRWK=
MOLT-16MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvCTWM2OD1{LkC3NFU5KCEQvF2=MlvtV2FPT0WU
NBsusSRMoe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PBb2lEPTB;Mj6wPVg5QSBizszNM1\XS3NCVkeHUh?=
TK10MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJwMUO0OVghKM7:TR?=M3P0R3NCVkeHUh?=
CAL-39NGTUT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJwMUS0PEAh|ryPMonhV2FPT0WU
NCI-H2030NUfzV3puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHRPIE2UUN3ME2yMlE5QTd|IDFOwG0>MVrTRW5ITVJ?
HCT-116NXnQV5hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLofHR4UUN3ME2yMlIzQTh2IDFOwG0>MlLBV2FPT0WU
HTC-C3NEPJbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJwMk[4NlQhKM7:TR?=NYLW[5ZDW0GQR1XS
TYK-nuNU\rWmdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LGPWlEPTB;Mj6zNFkxQSBizszNM1\ORXNCVkeHUh?=
FADUMl3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfZTWM2OD1{LkOyNlk3KCEQvF2=NGfKZoFUSU6JRWK=
A431M4\TfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTJwM{ewNlUhKM7:TR?=MVzTRW5ITVJ?
TE-11NEC3d|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJwM{iwNVkhKM7:TR?=M2LEeHNCVkeHUh?=
CAL-12TMlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\WTWVKSzVyPUKuOFA1OTdiIN88US=>M2DhfnNCVkeHUh?=
DBNIHmVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYroSJVsUUN3ME2yMlQzQDZ7IDFOwG0>NXfQbFM1W0GQR1XS
L-363M4C5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTJwNEO1NFchKM7:TR?=MYnTRW5ITVJ?
MSTO-211HMoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTJwNk[zPVEhKM7:TR?=NFfUW4hUSU6JRWK=
SK-UT-1MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXOc5BKSzVyPUKuO|E1ODZiIN88US=>NGCyfmFUSU6JRWK=
RPMI-8226NGHE[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn35TWM2OD1{LkezNVY1KCEQvF2=NYXyO5JTW0GQR1XS
SF295NIi2ZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVf2fYxzUUN3ME2yMlc1OzFiIN88US=>MmXiV2FPT0WU
OS-RC-2MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvu[INKSzVyPUKuO|Y3PzNiIN88US=>NFrySZFUSU6JRWK=
SK-MEL-24NWmzT3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;VdWlEPTB;Mj63PFIzPCBizszNNXPtZpNrW0GQR1XS
COR-L23NIe3TZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJwN{m0OlQhKM7:TR?=NY[yUIxDW0GQR1XS
MHH-PREB-1NWqycHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTJwOECxOlEhKM7:TR?=NXS4NIVjW0GQR1XS
SK-N-DZM{KwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3IWnhKSzVyPUKuPFE3OzhiIN88US=>NUT2ZnlzW0GQR1XS
OMC-1M3i2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPleG1KSzVyPUKuPFUxODNiIN88US=>MlLnV2FPT0WU
SK-MEL-2NEXIfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3yfJZKSzVyPUKuPFkzPDNiIN88US=>NXrFVGFWW0GQR1XS
SASNX;5To9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrvR5BKSzVyPUKuPVk1OTViIN88US=>M1j1bHNCVkeHUh?=
EPLC-272HNXXrVXk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e0c2lEPTB;Mz6wNFI{PSBizszNNUTVTXZCW0GQR1XS
8505CNY\1XFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLtTWM2OD1|LkGwN|AyKCEQvF2=NIHy[oNUSU6JRWK=
EW-11NXjxUFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2SyV2lEPTB;Mz6xOFI4PyBizszNM4m1[HNCVkeHUh?=
YKG-1MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTNwMUS3NFYhKM7:TR?=MV3TRW5ITVJ?
EC-GI-10M125UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmX1TWM2OD1|LkG3NlY{KCEQvF2=NYq1NGFEW0GQR1XS
SK-LU-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3XTWM2OD1|LkG4OFE5KCEQvF2=NYjYXmg4W0GQR1XS
P30-OHKM{HoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPZdm1KSzVyPUOuNlAyOTdiIN88US=>NVj5d|RHW0GQR1XS
T-24MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTNwMkG4NVQhKM7:TR?=MWDTRW5ITVJ?
HSC-2MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHPcJZZUUN3ME2zMlIzOjN{IDFOwG0>M3y2cXNCVkeHUh?=
SK-MES-1NX6wT3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDBV4dKSzVyPUOuNlQ5OjliIN88US=>MkXtV2FPT0WU
SW48MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7wTWM2OD1|LkK1OFg3KCEQvF2=M3\ndnNCVkeHUh?=
ME-180MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXjTWM2OD1|LkK2NFUyKCEQvF2=NUfvcFlqW0GQR1XS
NCI-H2009MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XUOWlEPTB;Mz6yPVAyKCEQvF2=MlrRV2FPT0WU
HL-60NXvuN3lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkX6TWM2OD1|LkK5NVMhKM7:TR?=NHr2NldUSU6JRWK=
NCI-N87Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LDVWlEPTB;Mz6zNFE4OiBizszNNVLQTGVnW0GQR1XS
GMS-10NXvs[nZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTuTWM2OD1|LkO0NFg3KCEQvF2=MWLTRW5ITVJ?
SCHMn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml:xTWM2OD1|LkSwPFQ1KCEQvF2=MX\TRW5ITVJ?
C-33-AMl3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M330d2lEPTB;Mz60NVQzOSBizszNNH3wTWVUSU6JRWK=
NCI-H1703NGXFUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHUWZNKSzVyPUOuOFE5OTJiIN88US=>MoXpV2FPT0WU
A427NVLIO|RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\0NmlKSzVyPUOuOFYyOjRiIN88US=>Mom2V2FPT0WU
MOLT-4Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEP2dYlKSzVyPUOuOFgyQTliIN88US=>NG\4O2JUSU6JRWK=
NCI-H1792NGnpPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nIWGlEPTB;Mz60PVgxOiBizszNNHX0So5USU6JRWK=
NCI-H1650MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXYXnN[UUN3ME2zMlU4OjliIN88US=>NVLnT4hjW0GQR1XS
H-EMC-SSNGC5RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUP1WHJEUUN3ME2zMlU5PTZ7IDFOwG0>MW\TRW5ITVJ?
SW982MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvyTWM2OD1|LkW4PFI6KCEQvF2=MmnqV2FPT0WU
DSH1NEjmdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTNwNkSxNlIhKM7:TR?=MV3TRW5ITVJ?
NOS-1NXTFVGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\QVmlEPTB;Mz62OFI4PiBizszNNVjHUYhrW0GQR1XS
BT-549M{POeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTNwNke4OVQhKM7:TR?=MmPQV2FPT0WU
HuCCT1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M16wWGlEPTB;Mz63OFE4PyBizszNMVnTRW5ITVJ?
NCI-H1755MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHiU3Q6UUN3ME2zMlk3QTdzIDFOwG0>NWHuZ5I1W0GQR1XS
KYSE-450NVfIOHpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVm4dFduUUN3ME2zMlk3QTl5IDFOwG0>M{nYbnNCVkeHUh?=
MIA-PaCa-2NGrhUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljJTWM2OD1|Lkm3NlkhKM7:TR?=MnPOV2FPT0WU
U-266MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXG1dm93UUN3ME2zMlk4PDhzIDFOwG0>MUjTRW5ITVJ?
MewoNY[xPZAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;0OWlEPTB;ND6wOlM3OSBizszNMnTvV2FPT0WU
KYSE-520M1HjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTRwMEm3PVkhKM7:TR?=NX71PItiW0GQR1XS
MN-60MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHjTWM2OD12LkGwOVAyKCEQvF2=MYjTRW5ITVJ?
Ramos-2G6-4C10NIPVSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXL5[WcxUUN3ME20MlE3PzN7IDFOwG0>Mny1V2FPT0WU
SK-MEL-1M1;TZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwMUi2PVUhKM7:TR?=Mo\wV2FPT0WU
ABC-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPoTWM2OD12LkKzN|M{KCEQvF2=MlLIV2FPT0WU
CAKI-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTRwMkS1O|EhKM7:TR?=M4jWXHNCVkeHUh?=
HOSMoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rEfmlEPTB;ND6yPVE1OSBizszNMkL3V2FPT0WU
SN12CMljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTRwM{SyOFQhKM7:TR?=MXnTRW5ITVJ?
NB13Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTRwM{ezOVUhKM7:TR?=NHflWJVUSU6JRWK=
M14MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrScnYzUUN3ME20MlQ5Pzl{IDFOwG0>M17MNXNCVkeHUh?=
GP5dNEW4PG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTRwNUCxNkAh|ryPNVSwUFNLW0GQR1XS
NCI-H720M3HvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEP2eFlKSzVyPUSuOVM3OTJiIN88US=>MkTKV2FPT0WU
D-423MGNG\OV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\DTWM2OD12LkWzPVI1KCEQvF2=NGHJV2RUSU6JRWK=
ChaGo-K-1NV:1W2dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFOxfHZKSzVyPUSuOVk2PTliIN88US=>MkHsV2FPT0WU
MEL-HONEDuRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTRwNkGyOlEhKM7:TR?=MWXTRW5ITVJ?
MHH-ES-1NH[wNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULDNpM6UUN3ME20MlYzPDFzIDFOwG0>NHn5NXFUSU6JRWK=
KYSE-270MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfOe2ZZUUN3ME20MlY2OTJ4IDFOwG0>MUTTRW5ITVJ?
GI-ME-NMlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{f6fmlEPTB;ND63NVI6OSBizszNMYfTRW5ITVJ?
HOP-92M{XHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\zcmlEPTB;ND64NVM4QSBizszNMmO3V2FPT0WU
MKN1NVz2cGh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jKO2lEPTB;ND64N|kyPCBizszNNWjYWmdVW0GQR1XS
ML-2NVS0bJlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXy2e4g3UUN3ME20Mlg2PjJ4IDFOwG0>MmnlV2FPT0WU
RO82-W-1NWezcGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\iTWM2OD12LkmyPVghKM7:TR?=NWKzO|h6W0GQR1XS
G-361M2iwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fxN2lEPTB;NT6wNVAxOyBizszNNWLT[2p7W0GQR1XS
HC-1M4XYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTVwMEOyPVEhKM7:TR?=NWjK[WdrW0GQR1XS
EW-24NX33OpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HuO2lEPTB;NT6wOFA{QCBizszNM4TF[HNCVkeHUh?=
HuP-T4NHG2TGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTVwMUSzN|QhKM7:TR?=MUjTRW5ITVJ?
8-MG-BAM4jnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWq5W45xUUN3ME21MlM1OjhiIN88US=>MWPTRW5ITVJ?
HGC-27MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\wPGlEPTB;NT6zO|Y5OiBizszNNXThTYlmW0GQR1XS
TE-12NFnSWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{Cyc2lEPTB;NT60NVU5PSBizszNM3fU[HNCVkeHUh?=
GT3TKBMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M320b2lEPTB;NT60OFIyOiBizszNM{LJZXNCVkeHUh?=
DOHH-2Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPKTWM2OD13LkS1PVg3KCEQvF2=MVzTRW5ITVJ?
Ca-SkiMlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DrcWlEPTB;NT60OlEyPSBizszNM1zmUXNCVkeHUh?=
A172MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlOzTWM2OD13LkW0PVI2KCEQvF2=MlS4V2FPT0WU
EGI-1NGi2N5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[yWGtpUUN3ME21MlU5QTN6IDFOwG0>NFjjSWhUSU6JRWK=
MZ2-MELMlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjzWolKSzVyPUWuOlE1QDZiIN88US=>MXvTRW5ITVJ?
SW1710M3Xidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1GwSmlEPTB;NT62PVA6OSBizszNM2XDd3NCVkeHUh?=
HT-144MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTVwN{K2PFUhKM7:TR?=NHfZVW9USU6JRWK=
PA-1NELY[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfmTGJKSzVyPUWuPFE5QTNiIN88US=>M1zzcXNCVkeHUh?=
HCC1937M2nMOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTVwOEO5NlkhKM7:TR?=NXfnR5dVW0GQR1XS
SK-OV-3NIH1R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\lcHJKSzVyPUWuPVEyOjFiIN88US=>NYDxSYdWW0GQR1XS
K5NULWUm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXSclR7UUN3ME22MlA2OTdiIN88US=>M{j4T3NCVkeHUh?=
NMC-G1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfHTWM2OD14LkC3O|k4KCEQvF2=M{D6eXNCVkeHUh?=
MDA-MB-361MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rxZ2lEPTB;Nj6wPVI3OSBizszNMVHTRW5ITVJ?
EKVXMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PIZ2lEPTB;Nj6xN|UxOSBizszNNHvJbFRUSU6JRWK=
ES7MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2H4VmlEPTB;Nj6xOlEyPSBizszNNF3se49USU6JRWK=
KS-1M{KwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nDfGlEPTB;Nj6xO|k6OyBizszNMXPTRW5ITVJ?
NCI-H661NIDxUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PkOmlEPTB;Nj6xPFA5OSBizszNNV\pSFBqW0GQR1XS
ES8M2D6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\nTWM2OD14LkG4NFgzKCEQvF2=Mnf0V2FPT0WU
NCI-H23MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrOU4pKSzVyPU[uNlE5OTZiIN88US=>Mn;MV2FPT0WU
T47DNWDRbZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTZwMk[0OVchKM7:TR?=NFvTfVVUSU6JRWK=
A2780NEHme21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPtWJdKSzVyPU[uN|c4ODFiIN88US=>NGq0SYtUSU6JRWK=
SCC-4MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHuS4xKSzVyPU[uOFM2PjFiIN88US=>M2D4dXNCVkeHUh?=
VA-ES-BJMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rtc2lEPTB;Nj65O|A1OyBizszNMYnTRW5ITVJ?
no-11MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTdwMU[0NUAh|ryPMWLTRW5ITVJ?
KU-19-19NXm1XmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXlZmtKSzVyPUeuNVY1PzZiIN88US=>NUn2SpA1W0GQR1XS
MKN45NXjOWXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXIOY1KSzVyPUeuNVg3QTliIN88US=>MXPTRW5ITVJ?
SCC-25MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLSfHRKSzVyPUeuNlM1OTRiIN88US=>MlPzV2FPT0WU
ETK-1MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTdwMkW1NVQhKM7:TR?=MorpV2FPT0WU
COR-L88NIPGcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DzU2lEPTB;Nz6yPVMyQSBizszNNEjCZllUSU6JRWK=
8305CNVX6XIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DRe2lEPTB;Nz6zNlQ6OiBizszNNXPjeo1rW0GQR1XS
Detroit562M2joWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHaTWM2OD15LkOyOVA3KCEQvF2=MWXTRW5ITVJ?
SNU-449MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7jTWM2OD15LkO3OlUyKCEQvF2=M1TtbHNCVkeHUh?=
A704MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HxV2lEPTB;Nz6zPFI4QCBizszNNVHsWoFGW0GQR1XS
D-502MGM2HQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTdwM{i0O|MhKM7:TR?=Mkf4V2FPT0WU
NCI-H2228MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTdwNEG0OVghKM7:TR?=NGnBN|RUSU6JRWK=
CHP-212M1\aRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDaXpdyUUN3ME23MlUyQDl4IDFOwG0>MlfiV2FPT0WU
VMRC-RCZNYjyW2E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYL6bphqUUN3ME23MlU6ODZ4IDFOwG0>MXrTRW5ITVJ?
RPMI-2650NEflc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2q2U2lEPTB;Nz63NFMyOiBizszNNIK3RW5USU6JRWK=
HCC2218MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XOV2lEPTB;Nz63NlI2QCBizszNM3fsdXNCVkeHUh?=
GCTM2fMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTdwOEKxO|IhKM7:TR?=NIDpNHFUSU6JRWK=
SW780MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITvcpJKSzVyPUeuPVkxPiBizszNMVXTRW5ITVJ?
KMOE-2NFfwXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRThwMESwO{Ah|ryPNELGeGhUSU6JRWK=
KYSE-180MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NID0d2lKSzVyPUiuNFg3PDhiIN88US=>NXK2eGhVW0GQR1XS
TE-1NGXSSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DyTmlEPTB;OD6xNVA2PyBizszNMlL4V2FPT0WU
OAW-42M3PHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fzd2lEPTB;OD6yOVQ6PiBizszNMWjTRW5ITVJ?
VM-CUB-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\TSIlKSzVyPUiuNlg{PjRiIN88US=>MU\TRW5ITVJ?
ECC10MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{L0XGlEPTB;OD6yPFM6PyBizszNMXnTRW5ITVJ?
SW1573MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nWT2lEPTB;OD60OFQ3PSBizszNNF;TTmxUSU6JRWK=
NCI-H1299NE\Sd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjySHVKSzVyPUiuOVk4PzRiIN88US=>M2DabHNCVkeHUh?=
ALL-PONULqdoo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRThwNk[1PVchKM7:TR?=MoSyV2FPT0WU
OVCAR-5MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPxRWFJUUN3ME24Mlc4PjJ3IDFOwG0>MYXTRW5ITVJ?
NCI-SNU-5MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDiTWM2OD16LkizNFAyKCEQvF2=NFLIPGpUSU6JRWK=
NCI-H2342NGPocIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRThwOEOxNFEhKM7:TR?=M4W4UnNCVkeHUh?=
RPMI-7951NFnGdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLJTWM2OD16Lki0NVU4KCEQvF2=MUTTRW5ITVJ?
RCM-1M4TV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPa[WFpUUN3ME25MlA5OTR3IDFOwG0>NH23bmxUSU6JRWK=
DaoyMkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3DXWxKSzVyPUmuNVIxOjhiIN88US=>MkjuV2FPT0WU
HCC1395M3TEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH:zO2NKSzVyPUmuN|A5QTZiIN88US=>NUDLTHEzW0GQR1XS
786-0Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfvc4VKSzVyPUmuN|YxOjZiIN88US=>MmjBV2FPT0WU
GAMGMl\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\vTWM2OD17Lk[1OVM1KCEQvF2=NYL2PZF3W0GQR1XS
HCC1954MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTlwOEW4OVkhKM7:TR?=NHXYNVRUSU6JRWK=
NCI-H1838Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzZTWM2OD17LkmwN|cyKCEQvF2=NGG5[4RUSU6JRWK=
SW620NVq0bGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPYTWM2OD17Lkm1N|U4KCEQvF2=NIPFZnFUSU6JRWK=
NCI-H358MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXuXJhwUUN3ME2xNE41OTl5IDFOwG0>MoHJV2FPT0WU
NCI-H1793Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HMNmlEPTB;MUCuOFI1QCBizszNMYnTRW5ITVJ?
NCI-H1666MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUj5WHV7UUN3ME2xNE41OzV3IDFOwG0>M4DEeHNCVkeHUh?=
MZ7-melNHfEbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIWyeXFKSzVyPUGwMlQ4PTNiIN88US=>MU\TRW5ITVJ?
MDA-MB-175-VIIM2HjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrrWngyUUN3ME2xNE43Ozl4IDFOwG0>MVXTRW5ITVJ?
COLO-829NGnSbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17uS2lEPTB;MUCuPFAxPCBizszNNYDvVmpXW0GQR1XS
RVH-421M3niPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDCTWM2OD1zMT6xOVIhKM7:TR?=MXLTRW5ITVJ?
A549M3;xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTFzLkK0O|ghKM7:TR?=NGHTZotUSU6JRWK=
DJM-1NXjYOHVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\4WpVKSzVyPUGxMlM5OzNiIN88US=>NWjwb2FTW0GQR1XS
IST-MEL1NYi2TVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\HZnBKSzVyPUGxMlc{OTliIN88US=>MV\TRW5ITVJ?
BENNGX1NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLKeGlKSzVyPUGxMlc1ODJiIN88US=>NX;FZ29yW0GQR1XS
KM12NUDHelZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfnTWM2OD1zMT65NFkyKCEQvF2=Mm\vV2FPT0WU
HuO9NIX1clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTF{LkC2OlYhKM7:TR?=NInLWnpUSU6JRWK=
U-2-OSMmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTHTWM2OD1zMj6wPFk{KCEQvF2=NYHaVnMyW0GQR1XS
RH-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\ZTWFoUUN3ME2xNk41PDd{IDFOwG0>NYXWbo8zW0GQR1XS
NCI-H1048M3;wWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MomyTWM2OD1zMj61OVA3KCEQvF2=MoO2V2FPT0WU
Mo-TNX;sV5dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zRc2lEPTB;MUKuO|MxPyBizszNMnW2V2FPT0WU
KYSE-150M375U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\HUmlEPTB;MUKuO|Q2PSBizszNNV\SfoZmW0GQR1XS
A388MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzFPItKSzVyPUGyMlc4OTNiIN88US=>M1\vcXNCVkeHUh?=
NCI-SNU-1NELjNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mle0TWM2OD1zMj64NFQ3KCEQvF2=M2\ienNCVkeHUh?=
HELMojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrzdGN[UUN3ME2xNk45OjF{IDFOwG0>MnPOV2FPT0WU
UM-UC-3NWTQc41yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF{Lki4O|QhKM7:TR?=MXrTRW5ITVJ?
TGBC24TKBNYXPVFVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVviVXhYUUN3ME2xN{4xOjZ5IDFOwG0>MUjTRW5ITVJ?
SW626MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;LPWlEPTB;MUOuNlQ5PSBizszNNXu1N25GW0GQR1XS
ES6M{\YRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4GzZmlEPTB;MUOuNlUyOiBizszNMUPTRW5ITVJ?
NCI-H2029NInhRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fkNWlEPTB;MUOuPFExQCBizszNNEjpfoRUSU6JRWK=
RXF393NHfoSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HYNGlEPTB;MUOuPVkzPyBizszNMXvTRW5ITVJ?
HMV-IIMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTF2LkC3PEAh|ryPM3HrSHNCVkeHUh?=
EW-22NEGzPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEf2NXBKSzVyPUG0MlE2ODJiIN88US=>NUXxVYxjW0GQR1XS
AsPC-1Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPk[pRKSzVyPUG0MlU3PCBizszNMYnTRW5ITVJ?
COLO-678NVjxV5k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fwcGlEPTB;MUSuO|I4OSBizszNNWrzPYx1W0GQR1XS
HCT-15Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLDU3hiUUN3ME2xOE45QDV3IDFOwG0>MWXTRW5ITVJ?
HCE-TNX[2Rpo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHT4XotKSzVyPUG0Mlg5PzRiIN88US=>NUHTdog2W0GQR1XS
SF539NH\jXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF3LkC2OFMhKM7:TR?=MUfTRW5ITVJ?
AU565M{\6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfFTWM2OD1zNT6yNFk3KCEQvF2=MnPLV2FPT0WU
JVM-2MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NISzSJZKSzVyPUG1MlI3QDFiIN88US=>NWHNV|Y1W0GQR1XS
CaR-1NGXXZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLlZ49pUUN3ME2xOU41PDF{IDFOwG0>M2XoPXNCVkeHUh?=
23132-87NUHDTlZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLaTWM2OD1zNT64OFk2KCEQvF2=MWfTRW5ITVJ?
A673NID2c3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDDTWM2OD1zNT65OlM3KCEQvF2=M3;TUHNCVkeHUh?=
KYSE-410NIfqc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnJTWM2OD1zNj6wNlkhKM7:TR?=MoPjV2FPT0WU
TE-9Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTF4LkC2NkAh|ryPM1jQbXNCVkeHUh?=
LU-139MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLJTWM2OD1zNj6xPFI{KCEQvF2=M3HMW3NCVkeHUh?=
GCIYMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nUPWlEPTB;MU[uNVkyPiBizszNMkK3V2FPT0WU
JEG-3M4i1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnxfFFuUUN3ME2xOk4zPSBizszNM1faTHNCVkeHUh?=
RT-112Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rrPGlEPTB;MU[uOFE1OyBizszNMWTTRW5ITVJ?
COLO-680NNXntcFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnDbpRKSzVyPUG2MlUyODhiIN88US=>MXTTRW5ITVJ?
LU-134-ANXjGOIo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPKbZVOUUN3ME2xOk46QDl|IDFOwG0>M{LOV3NCVkeHUh?=
MFM-223MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\0XmlEPTB;MUeuNVU{PSBizszNNFvuNJdUSU6JRWK=
SF126M2KzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3uVItKSzVyPUG3MlE4ODFiIN88US=>M4DUW3NCVkeHUh?=
NCI-H28M{DNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3H6SGlEPTB;MUeuNlA3PiBizszNNGrqfnJUSU6JRWK=
BFTC-905NWf4XpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXHNHVrUUN3ME2xO{41QDN{IDFOwG0>M1n2OXNCVkeHUh?=
SCC-9NWTPelRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTF5Lk[yPFUhKM7:TR?=M4mycHNCVkeHUh?=
KNS-62NX3ZTnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PFe2lEPTB;MUeuOlYzQSBizszNMUHTRW5ITVJ?
Hs-578-TNGnYTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XNOWlEPTB;MUeuPFE1QSBizszNMkjNV2FPT0WU
D-336MGMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPUUVVKSzVyPUG3MlgzQTRiIN88US=>NHW2eIpUSU6JRWK=
NCI-H82NI\YS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzuTWM2OD1zOD6wNVg{KCEQvF2=MlmxV2FPT0WU
EFM-19MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFn6b3lKSzVyPUG4MlA2PzdiIN88US=>MkjoV2FPT0WU
TGBC11TKBNVu0cY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjXe3NKSzVyPUG4MlExOjFiIN88US=>Mo\tV2FPT0WU
HEC-1M2LD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrTTWM2OD1zOD6yPVE5KCEQvF2=NIP5c5VUSU6JRWK=
HuP-T3NXL6VZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHP[FFpUUN3ME2xPE42QTJ7IDFOwG0>NXfPWlRIW0GQR1XS
SF268MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zSNmlEPTB;MUiuOlcxOiBizszNMWjTRW5ITVJ?
COLO-792M170O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnhTWM2OD1zOD63PVk4KCEQvF2=M{TUWXNCVkeHUh?=
HLEM4PHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTF6LkizN|EhKM7:TR?=MUTTRW5ITVJ?
A204NV3UfnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYnJR|UxRTF6LkmxOlQhKM7:TR?=MmjRV2FPT0WU
CAL-72MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlX6TWM2OD1zOT6wPFc4KCEQvF2=NUjRe4xVW0GQR1XS
U031Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXkcodKSzVyPUG5MlQ6ODliIN88US=>NHnmSY9USU6JRWK=
FTC-133MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljkTWM2OD1zOT65N|A1KCEQvF2=M2PtUXNCVkeHUh?=
SK-MEL-28MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfHdnJKSzVyPUKwMlM4PjFiIN88US=>MoTRV2FPT0WU
KGNM3zrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3f5ZmlEPTB;MkCuOFY6QSBizszNM3;tZXNCVkeHUh?=
HCC2998NECzTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGToSnVKSzVyPUKxMlM6OjZiIN88US=>MVrTRW5ITVJ?
GOTOM1n1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTMc5h2UUN3ME2yNU41QDViIN88US=>MXHTRW5ITVJ?
AGSNX\nbZNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJzLki0OVEhKM7:TR?=M2DOfXNCVkeHUh?=
EW-13MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzxXVNJUUN3ME2yNk4yODJ{IDFOwG0>MULTRW5ITVJ?
P12-ICHIKAWAM4\PR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\l[WlEPTB;MkKuNVYxOyBizszNMVfTRW5ITVJ?
NCI-H1395NUPYPJMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTJ{LkK5NFchKM7:TR?=MYjTRW5ITVJ?
A2058MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHodoJKSzVyPUKyMlQ{PCBizszNNV:5[ZF5W0GQR1XS
SH-4NYfUSnhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTJ{LkewOFUhKM7:TR?=MVXTRW5ITVJ?
DoTc2-4510M2r2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LRXGlEPTB;MkOuOlQ4OiBizszNNXXpfnB7W0GQR1XS
MMAC-SFNYfuOJhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LzWGlEPTB;MkOuOlkyOSBizszNM2nGXnNCVkeHUh?=
NCI-H510ANWHZ[oNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTJ|Lke5N|khKM7:TR?=MlTBV2FPT0WU
HDLM-2NGT6W|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TBdGlEPTB;MkSuNVQ3KCEQvF2=Mkf4V2FPT0WU
KINGS-1MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJ2LkK0NkAh|ryPNE\NW5RUSU6JRWK=
NCI-H1648M3jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\yWIhFUUN3ME2yOE41ODJ2IDFOwG0>MULTRW5ITVJ?
HCC1187MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\3O2JKSzVyPUK1MlAzOzViIN88US=>NHTwNFFUSU6JRWK=
BALL-1M4jYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzvTWM2OD1{NT6yNFYzKCEQvF2=MXPTRW5ITVJ?
SBC-1Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfHSVJKSzVyPUK1MlI6QTNiIN88US=>MV;TRW5ITVJ?
BFTC-909MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfncJU2UUN3ME2yOU4{PTVzIDFOwG0>MV;TRW5ITVJ?
MOLT-13MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M125Z2lEPTB;MkWuOlc1PCBizszNMXjTRW5ITVJ?
SW1990M2L2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:xV3VKSzVyPUK1Mlk3PTViIN88US=>NGXQXVBUSU6JRWK=
DK-MGNFTPUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHYTWM2OD1{Nj6wOFQ{KCEQvF2=M1v6T3NCVkeHUh?=
TE-8NWftcnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T6NGlEPTB;Mk[uNFY3QCBizszNM{W1SnNCVkeHUh?=
BeckerNH7CR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7STWM2OD1{Nj6xOVc1KCEQvF2=NEnafXhUSU6JRWK=
KYSE-70MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJ4LkWzNVchKM7:TR?=MXHTRW5ITVJ?
MKN7MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzYTY5rUUN3ME2yO{44PDd7IDFOwG0>MVXTRW5ITVJ?
D-392MGM{\vcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojDTWM2OD1{Nz63Olk1KCEQvF2=MYTTRW5ITVJ?
NH-12MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzhOIdrUUN3ME2yPE4yOjJ7IDFOwG0>NIr0WY5USU6JRWK=
EW-18M3HJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXvTWM2OD1{OD6yNlE5KCEQvF2=NETRb29USU6JRWK=
LCLC-97TM1NYTINoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGP1NVlKSzVyPUK4MlI4PjJiIN88US=>MnjUV2FPT0WU
NCI-H1770M3\nNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTJ6LkO1OlYhKM7:TR?=NVT4[XNsW0GQR1XS
BT-20NEXqZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LqbGlEPTB;MkiuN|Y5PSBizszNNHXOc|lUSU6JRWK=
DBTRG-05MGM3XxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XaUmlEPTB;MkiuOFg{QCBizszNNX;p[FgyW0GQR1XS
HPAF-IIMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILzNYVKSzVyPUK4Mlc4QSBizszNMoqyV2FPT0WU
SW837NXvsN4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHiTWM2OD1{OT6zN|g2KCEQvF2=M4PSVHNCVkeHUh?=
647-VNG\HdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mly3TWM2OD1{OT63NFA{KCEQvF2=Ml;VV2FPT0WU
J82NXHlVWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX22bI5pUUN3ME2yPU45ODF|IDFOwG0>MWTTRW5ITVJ?
MC116NYK2UHROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTNyLkC3N|MhKM7:TR?=M3LKd3NCVkeHUh?=
NCI-H69Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXs[4lKSzVyPUOwMlYxQTNiIN88US=>NFj4R4dUSU6JRWK=
NB6MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nHWWlEPTB;M{GuN|YzQSBizszNM3HFSXNCVkeHUh?=
CAL-120M1LMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTN{LkSzNVchKM7:TR?=NYnXWGhkW0GQR1XS
U-87-MGNYTYeo4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTN|LkCyOVEhKM7:TR?=Mn:0V2FPT0WU
NCI-H1304MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoT2TWM2OD1|Mz6wN|U1KCEQvF2=NX6wOXNjW0GQR1XS
YH-13NW\qPGpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\NN|FWUUN3ME2zN{4zPTN3IDFOwG0>NXLhUJRSW0GQR1XS
RMG-IM3rhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHDeYFKSzVyPUOzMlQzQDViIN88US=>NInCUllUSU6JRWK=
LU-65MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vJS2lEPTB;M{SuNVQxQCBizszNM{TM[HNCVkeHUh?=
GB-1MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13QW2lEPTB;M{WuNFczQSBizszNNVXVNW1YW0GQR1XS
DU-4475NU\IbHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moq5TWM2OD1|NT6xOVU{KCEQvF2=MYnTRW5ITVJ?
SBC-5NWDEe49rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTGPFZLUUN3ME2zOk42QTB{IDFOwG0>MnvEV2FPT0WU
OE33NF7pPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XDc2lEPTB;M{euO|U4PyBizszNNELnWW1USU6JRWK=
C8166MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY[zRnJlUUN3ME2zPE42OjZ5IDFOwG0>MmX1V2FPT0WU
COLO-684MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDwTWM2OD1|OD63OFI5KCEQvF2=NEeycIdUSU6JRWK=
NCI-H1155M2DsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTN7LkC0O|EhKM7:TR?=NXvQNJRQW0GQR1XS
ATN-1Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWj1Xm1VUUN3ME2zPU44Pzl{IDFOwG0>MX\TRW5ITVJ?
KARPAS-299NHfJbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mof1TWM2OD1|OT64N|khKM7:TR?=MYLTRW5ITVJ?
KNS-81-FDNUizeGltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjkS2RKSzVyPUSwMlM3ODRiIN88US=>M3zKd3NCVkeHUh?=
NCI-H1563NYrTc2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PvTWlEPTB;NEGuOVA{QSBizszNMWLTRW5ITVJ?
NB14NUT1TIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTR{LkeyOlMhKM7:TR?=MYrTRW5ITVJ?
COLO-800M4DMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHpTWM2OD12Mj64OVE4KCEQvF2=MWnTRW5ITVJ?
MS-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\kZWlEPTB;NEOuNFQ5OyBizszNMUnTRW5ITVJ?
OVCAR-8M3K3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjH[otKSzVyPUSzMlY5ODliIN88US=>M1LUZXNCVkeHUh?=
SK-PN-DWMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1qwVGlEPTB;NEOuPFc4PiBizszNMYLTRW5ITVJ?
G-402NEjzSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3u0dmlEPTB;NEOuPVAxPiBizszNMnm4V2FPT0WU
NCI-H2291NWi3XG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnu0TWM2OD12ND64NFE4KCEQvF2=NF[0eppUSU6JRWK=
PC-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3tTWM2OD12NT64NFI{KCEQvF2=NV\M[YlsW0GQR1XS
NCI-H1581MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf1XJZKSzVyPUS1Mlk5QDliIN88US=>NWrLb3lYW0GQR1XS
SW1116M2nQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojVTWM2OD12Nz6wNVgzKCEQvF2=NIm5ZpJUSU6JRWK=
ZR-75-30NXLOXWROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nFUWlEPTB;NEeuNFI{QSBizszNNXXITWtwW0GQR1XS
OCI-AML2NELVbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYOzV3pIUUN3ME20O{4xQTF6IDFOwG0>NX73eoo5W0GQR1XS
MDA-MB-231NWK1fmE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVH6R5ZKUUN3ME20O{43OjR7IDFOwG0>MYfTRW5ITVJ?
ES3NWrKVZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnLNWdKSzVyPUS4MlM2OjliIN88US=>M1P5eHNCVkeHUh?=
NCI-H630NXPVPFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTR7LkG3OFIhKM7:TR?=NH:0NplUSU6JRWK=
OE19MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTR7LkK5NFIhKM7:TR?=NH7kN21USU6JRWK=
NCI-H1573MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlznTWM2OD12OT62PFYyKCEQvF2=MYfTRW5ITVJ?
EW-1NEHKOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\m[WJiUUN3ME20PU46ODh2IDFOwG0>M4CwbHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-29)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02501330 Active, not recruiting Chronic Myelogenous Leukemia Pfizer July 2015 --
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Customer Product Validation (3)


Click to enlarge
Rating
Source J Virol 2011 85, 2296–2303. Bosutinib (SKI-606) purchased from Selleck
Method Endothelial cell permeability assay
Cell Lines Human endothelial cells
Concentrations 0-10 μM
Incubation Time 15-60 min
Results Figure C defines concentrations of kinase inhibitors which block ANDV-induced EC permeability approximately 50% (IC50s). IC50s of bosutinib are 100 nM and 10 μM. we next assessed the abilities of bosutinib to block ANDV-induced permeability at its IC50s from 15 to 60 min after VEGF addition, we find that bosutinib inhibited ANDV-induced permeability up to 40 to 50% but only at IC50s of 10 μM(Figure D).

Click to enlarge
Rating
Source J Biol Chem 2010 285, 7977–7985. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines Mouse sperm
Concentrations 0-50 μM
Incubation Time 60 min
Results In the case of SKI606, a sharp inhibitory effect was observed at 50 μM.

Click to enlarge
Rating
Source Dr. Pablo E.Visconti from University of Massachusetts. Bosutinib (SKI-606) purchased from Selleck
Method Western blot
Cell Lines sperm
Concentrations 50 μΜ
Incubation Time
Results PKA and tyrosine phosphorylation was rescue by Ser/Thr phosphatase inhibitors SKI-606 and SU6656.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us